Clinical trialNCT03487913CompletedPhase 2Interventional

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

SponsorPalladio BiosciencesEnrollment31Autosomal Dominant Polycystic Kidney Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2, open-label, parallel-group, multiple dose study designed to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan in Autosomal Dominant Polycystic Kidney Disease subjects with chronic kidney disease (CKD) in stages CKD1, CKD2 or CKD3.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Vicente E Torres, MD, PhD
Mayo Clinic
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Palladio Biosciences Clinical Site
Los Angeles, California, United States
Palladio Biosciences Clinical Site
Jacksonville, Florida, United States
Palladio Biosciences Clinical Site
Miami, Florida, United States
Palladio Biosciences Clinical Site
Miami, Florida, United States
Palladio Biosciences Clinical Site
Palmetto Bay, Florida, United States
Palladio Biosciences Clinical Site
Tampa, Florida, United States
Palladio Biosciences Clinical Site
Baltimore, Maryland, United States
Palladio Biosciences Clinical Site
Rochester, Minnesota, United States
Palladio Biosciences Clinical Site
Kansas City, Missouri, United States
Palladio Biosciences Clinical Site
Laurelton, New York, United States
Palladio Biosciences Clinical Site
Indiana, Pennsylvania, United States
Palladio Biosciences Clinical Site
Nashville, Tennessee, United States
Palladio Biosciences Clinical Site
Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

LIXIVAPTAN

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Sept 2018
Primary completion: 2 Dec 2019
Completion: 11 Feb 2020
Last update posted: 5 Dec 2022
Registered enrollment: 31
Registry id: NCT03487913

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.